EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cystathionine β‐Synthase Deficiency in the E‐ HOD Registry—Part II : Dietary and Pharmacological Treatment

Andrew A M Morris, Jitka Sokolová iD, Markéta Pavlíková iD, Florian Gleich iD, Stefan Kölker iD, Carlo Dionisi-Vici iD, Matthias R Baumgartner iD, Luciana Hannibal iD, Henk J Blom iD, Martina Huemer iD, Viktor Kožich iD, E‐HOD Consortium

Journal of Inherited Metabolic Disease · 2025-01 · 48 (1)

DOI: 10.1002/jimd.12844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 13.01.2025. Verfasst von Andrew A M Morris und 11 weiteren Autor:innen. Beteiligte Einrichtung: Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Trust, Manchester, UK. Hauptthemen laut MEDLINE: Homocystinuria, Pyridoxine, Cystathionine beta-Synthase. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Czech Republic, General University Hospital in Prague, Charles University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystathionine β‐synthase (CBS) deficiency (classical homocystinuria) has a wide range of severity. Mildly affected patients typically present as adults with thromboembolism and respond to treatment with pyridoxine. Severely affected patients usually present during childhood with learning difficulties, ectopia lentis and skeletal abnormalities; they are pyridoxine non‐responders (NR) or partial responders (PR) and require treatment with a low‐methionine diet and/or betaine. The European network and registry for Homocystinurias and methylation Defects (E‐HOD) has published management guidelines for CBS deficiency and recommended keeping plasma total homocysteine (tHcy) concentrations below 100 μmol/L. We have now analysed data from 311 patients in the registry to see how closely treatment follows the guidelines. Pyridoxine‐responsive patients generally achieved tHcy concentrations below 50 μmol/L, but many NRs and PRs had a mean tHcy considerably above 100 μmol/L. Most NRs were managed with betaine and a special diet. This usually involved severe protein restriction and a methionine‐free amino acid mixture, but some patients had a natural protein intake substantially above the WHO safe minimum. Work is needed on the methionine content of dietary protein as estimates vary widely. Contrary to the guidelines, most NRs were on pyridoxine, sometimes at dangerously high doses. tHcy concentrations were similar in groups prescribed high or low betaine doses and natural protein intakes. High tHcy levels were probably often due to poor compliance. Comparing time‐to‐event graphs for NR patients detected by newborn screening and those ascertained clinically showed that treatment could prevent thromboembolism (risk ratio 0.073) and lens dislocation (risk ratio 0.069).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HomocystinuriaPyridoxineCystathionine beta-SynthaseHumansRegistriesBetaineFemaleChildAdultMaleMethionineChild, PreschoolAdolescentInfantHomocysteineYoung AdultInfant, Newborn

Stichwörter der Autor:innen

betainehomocystinuriamethioninenewborn screeningprotein restrictionpyridoxine

Substanzen

BetainePyridoxineCystathionine beta-SynthaseMethionineHomocysteine

Autor:innen und Institutionen

  • Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Trust, Manchester, UK.
  • Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czechia.
  • Department of Probability and Mathematical Statistics, Charles University-Faculty of Mathematics and Physics, Prague, Czechia.
  • Centre for Pediatric and Adolescent Medicine, Department of Pediatrics I, Division of Pediatric Neurology and Metabolic Medicine, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
  • Division of Metabolism, Bambino Gesù Children's Research Hospital, Rome, Italy.
  • Division of Metabolism and Children's Research Center, University Children's Hospital, Zurich, Switzerland.

ORCID-Profile: Jitka Sokolová, Markéta Pavlíková, Florian Gleich, Stefan Kölker, Carlo Dionisi-Vici, Matthias R Baumgartner, Luciana Hannibal, Henk J Blom, Martina Huemer, Viktor Kožich

Förderung

  • Ministry of Health of the Czech Republic
  • General University Hospital in Prague
  • Charles University
  • Ministerstvo Zdravotnictví Ceské Republiky
  • Všeobecná Fakultní Nemocnice v Praze
  • Univerzita Karlova v Praze

Zitieren

APA

Morris, A. A. M., Sokolová, J., Pavlíková, M., Gleich, F., Kölker, S., Dionisi-Vici, C., Baumgartner, M. R., Hannibal, L., Blom, H. J., Huemer, M., Kožich, V., & E‐HOD Consortium (2025). Cystathionine β‐Synthase Deficiency in the E‐ HOD Registry—Part II : Dietary and Pharmacological Treatment. Journal of Inherited Metabolic Disease, 48(1). https://doi.org/10.1002/jimd.12844

Vancouver

Morris AAM, Sokolová J, Pavlíková M, Gleich F, Kölker S, Dionisi-Vici C, et al. Cystathionine β‐Synthase Deficiency in the E‐ HOD Registry—Part II : Dietary and Pharmacological Treatment. Journal of Inherited Metabolic Disease. 2025;48(1). doi:10.1002/jimd.12844

BibTeX
@article{Morris2025,
  author = {Morris, Andrew A M and Sokolová, Jitka and Pavlíková, Markéta and Gleich, Florian and Kölker, Stefan and Dionisi-Vici, Carlo and Baumgartner, Matthias R and Hannibal, Luciana and Blom, Henk J and Huemer, Martina and Kožich, Viktor and E‐HOD Consortium, E‐HOD Consortium},
  title = {Cystathionine β‐Synthase Deficiency in the E‐ HOD Registry—Part II : Dietary and Pharmacological Treatment},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  volume = {48},
  number = {1},
  doi = {10.1002/jimd.12844}
}
Kostenlos starten →